Abstract
Objectives
Neurokinin-1 receptor antagonists (NK1 RAs) are commonly coadministered with a 5-HT3 RA such as palonosetron to prevent nausea and vomiting induced by chemotherapy. Netupitant, a new highly selective NK1 RA, is both a substrate for and a moderate inhibitor of CYP3A4. Three studies were designed to evaluate the potential drug–drug interaction of netupitant with palonosetron and of the fixed dose combination of netupitant and palonosetron, NEPA, with an inhibitor (ketoconazole), an inducer (rifampicin) and a substrate (oral contraceptives) of CYP3A4.
Methods
Study 1 was a three-way crossover in 18 healthy subjects receiving netupitant alone, palonosetron alone, and the combination of both antiemetics. Studies 2 and 3 were two-way crossover trials where healthy subjects received NEPA (the fixed dose combination of netupitant and palonosetron). In study 2, 36 subjects received NEPA alone (day 1) and in combination with ketoconazole or rifampicin. In study 3, 24 healthy women received ethinylestradiol/levonorgestrel alone or in combination with NEPA (day 1).
Results
There were no significant pharmacokinetic interactions between netupitant and palonosetron. Ketoconazole increased netupitant area under curve (AUC) by 140 % and C max by 25 %. Rifampicin decreased netupitant AUC by 83 % and C max by 62 %. NEPA did not significantly affect exposure to ethinylestradiol, while systemic exposure to levonorgestrel increased by 40 %, but this was not considered clinically relevant.
Conclusions
There were no clinically relevant interactions between netupitant and palonosetron, or between NEPA and oral contraceptives. The coadministration of NEPA with inhibitors or inducers of CYP3A4 may require dose adjustments. Treatments were well tolerated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sun CC, Bodurka DC, Weaver CB, Rasu R, Wolf JK, Bevers MW, Smith JA, Wharton JT, Rubenstein EB (2005) Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 13(4):219–227
Feyer P, Jordan K (2011) Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 22(1):30–38
Roila F, Herrstedt J, Aapro M, Gralla RJ et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(5):v232–v243, www.mascc.org
Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC et al (2012) Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncology 29(31):4189–4198, www.asco.org
NCCN Clinical Practice Guidelines in Oncology: Antiemesis Version 1. (2012) www.nccn.org
Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39(8):1074–1080
Rubenstein EB, Slusher BS, Rojas C, Navari RM (2006) New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations. Cancer J 12(5):341–347
Gralla R, Lichinitser M, Van Der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14(10):1570–1577
Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S; 99–04 Palonosetron Study Group (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98(11):2473–2482
Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115–124, Epub 2009 Jan 8. Erratum in: Lancet Oncol. 2010 11(3):226
Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17(9):1441–1449
Rojas C, Li Y, Zhang J, Stathis M, Alt J, Thomas AG, Cantoreggi S, Sebastiani S, Pietra C, Slusher BS (2010) The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther 335(2):362–368, Epub 2010 Aug 19
Rojas C, Slusher BS (2012) Pharmacological mechanism of 5-HT3 and tachykinin NK-1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol 684(1–3):1–7, Epub 2012 Mar 9
Stathis M, Pietra C, Rojas C, Slusher BS (2012) Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol 689(1–3):25–30
Rizzi A, Campi B, Camarda V, Molinari S, Cantoreggi S, Regoli D, Pietra C, Calo' G (2010) In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist, Netupitant. Peptides 37(1):86–97
Giuliano C, Lovati E, Funk C, Potthast M, Pietra C, (2012) In vitro drug–drug interaction studies with the antiemetic drug Netupitant and its major metabolites (M1 and M2), involving main human cytochrome P450 isoenzymes. Annals of Oncology 23 (Supplement 9): ix499–ix527, doi:10.1093/annonc/mds416 (abstract 1618)
Lanzarotti C, Rossi G (2013) Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone. Support Care Cancer (this issue), doi:10.1007/s00520-013-1855-y
Palonosetron package insert (2012) Lugano, Switzerland. Helsinn Healthcare
Salsman JM, Grunberg SM, Beaumont JL, Rogers M, Paul D, Clayman ML, Cella D (2012) Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. J Natl Compr Canc Netw 10(2):149–157
Aapro MS, Walko CM (2010) Aprepitant: drug–drug interactions in perspective. Ann Oncol 21(12):2316–2323. doi:10.1093/annonc/mdq149, Epub 2010 May 20. Review
EMEND (package insert) (2013) Merck Sharp & Dohme Corp., a subsidiary of Merck & CO., Inc., Whitehouse Station
Blum RA, Majumdar A, McCrea J, Busillo J, Orlowski LH, Panebianco D, Hesney M, Petty KJ, Goldberg MR, Murphy MG, Gottesdiener KM, Hustad CM, Lates C, Kraft WK, Van Buren S, Waldman SA, Greenberg HE (2003) Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 25(5):1407–1419
Shah AK, Hunt TL, Gallagher SC, Cullen MT Jr (2005) Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Curr Med Res Opin 21(4):595–601
Adams LM, Johnson B, Zhang K, Yue L, Kirby LC, Lebowitz P, Stoltz R (2009) Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron. Support Care Cancer 17(9):1187–1193
Johnson B, Adams L, Lu E, Zhang K, Lebowitz P, Lates C, Blum R (2009) Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. Support Care Cancer 17(9):1177–1185
Sanchez RI, Wang RW, Newton DJ, Bakhtiar R, Lu P, Chiu SH, Evans DC, Huskey SE (2004) Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 32(11):1287–1292
Johnson BM, Adams LM, Zhang K, Gainer SD, Kirby LC, Blum RA, Apseloff G, Morrison RA, Schutz RA, Lebowitz PF (2010) Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist. J Clin Pharmacol 50(8):951–959
Acknowledgments
We thank Silvia Olivari Tilola, Helen Pentikis, Norman Nagl, Jennifer Vanden Burgt, Paul Ricigliano, and Silvia Sebastiani for their support in the manuscript preparation and Claudio Giuliano for both the inclusion of the preclinical data and for his expert advises.
Disclosure
This study was sponsored by Helsinn Healthcare SA. Anders Henriksson, Klaus Peter Kammerer, and Wolfgang Timmer received funding from Helsinn Healthcare to conduct this study. All other authors were employees of Helsinn Healthcare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Calcagnile, S., Lanzarotti, C., Rossi, G. et al. Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives. Support Care Cancer 21, 2879–2887 (2013). https://doi.org/10.1007/s00520-013-1857-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-013-1857-9